Minerva Biotechnologies
Minerva Biotechnologies is a clinical-stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine.
8
Funding Rounds
$113.7m
Money raised
Funding
Funding series
Funding Series Analysis
The company Minerva Biotechnologies has raised a total of $29.6m in funding over 8 rounds.
Key Insights:
- MINERVA BIOTECHNOLOGIES Corp Funding Round, February 2022: $25m
- Minerva Biotechnologies funding round, November 2010: $4.6m
- MINERVA BIOTECHNOLOGIES Corp funding round, October 2019: $12m
- MINERVA BIOTECHNOLOGIES Corp funding round, April 2019: $12m
- MINERVA BIOTECHNOLOGIES Corp funding round, October 2018: $31.2m
- MINERVA BIOTECHNOLOGIES Corp funding round, October 2014: $30m
- MINERVA BIOTECHNOLOGIES Corp funding round, November 2010: $5.9m
- MINERVA BIOTECHNOLOGIES CORP funding round, February 2010: $5m
MINERVA BIOTECHNOLOGIES Corp Funding Round, February 2022
$25m
Minerva Biotechnologies funding round, November 2010
$4.6m
MINERVA BIOTECHNOLOGIES Corp funding round, October 2019
$12m
MINERVA BIOTECHNOLOGIES Corp funding round, April 2019
$12m
MINERVA BIOTECHNOLOGIES Corp funding round, October 2018
$31.2m
MINERVA BIOTECHNOLOGIES Corp funding round, October 2014
$30m
MINERVA BIOTECHNOLOGIES Corp funding round, November 2010
$5.9m
MINERVA BIOTECHNOLOGIES CORP funding round, February 2010
$5m
Industries
Minerva Biotechnologies is active in the following industries: